Catriona Yale, Chief Development Officer at Akero Therapeutics, Inc. (AKRO), sold 16,946 shares at $37.80 ($642K) on 2025-04-15, disclosed to the SEC on 2025-04-16.
Scheduled sale ($642k) by Chief Development Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $37.80 | 7,873 | $298K | 46.4% |
| 2 | $37.80 | 7,873 | $298K | 46.4% |
| 3 | $38.62 | 1,200 | $46K | 7.2% |
| Total | $37.86 avg | 16,946 | $642K | 100% |
| Filing → |
| AKRO | SELL | 2025-06-20 | $179K | — | Filing → |
| AKRO | SELL | 2025-06-20 | $876K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $151K | — | Filing → |